Recherche
-
Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies
(DRUID Society Conf., DK, Copenhague)Communication dans un congrès avec actes -
Empirical economic analysis of orphan drug legislation impact on innovation
(Eur. Health Economic Association Conf., DE, Hamburg)Communication dans un congrès avec actes -
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021.
(2017)Document de travail - Pré-publication -
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies
(University of Chicago Press, 2019)Chapitre d'ouvrage -
Empirical Economic Analysis of Orphan DrugLegislation Impact on Innovation
(European Health Economics Association Conference, DE, HAMBURG)Communication dans un congrès avec actes -
Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies
(65th Annual Meeting of the French Economic Association,, FR, Nancy)Autre communication scientifique (congrès sans actes - poster - séminaire...) -
Empirical Economic Analysis ofOrphan Drug Innovation
(NBER Conference : Economic Dimensions of Personalized and Precision Medecine, US, New York)Communication dans un congrès avec actes -
Empirical Economic Analysis of Orphan Drug Innovation
(NBER Economic Dimensions of Personalized and Precision Medicine,, US, Santa Monica. CA,)Communication dans un congrès avec actes -
Empirical Economic Analysis of Orphan Drug Innovation
(NBER Economic Dimensions of Personalized and Precision Medicine, Columbia Univ., US, New York)Communication dans un congrès avec actes -
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021.
(2017)Document de travail - Pré-publication